[go: up one dir, main page]

CL2012002318A1 - Compuestos derivados de tieno [2,3-d]pirimidina, inhibidores de quinasa mnk1 y mnk2; composición farmaceutica; que los comprende; y su uso en el tratamiento de enfermedades metabolicas, hematopoyeticas, neurodegenerativas, renales, inflamatorias y cancer. - Google Patents

Compuestos derivados de tieno [2,3-d]pirimidina, inhibidores de quinasa mnk1 y mnk2; composición farmaceutica; que los comprende; y su uso en el tratamiento de enfermedades metabolicas, hematopoyeticas, neurodegenerativas, renales, inflamatorias y cancer.

Info

Publication number
CL2012002318A1
CL2012002318A1 CL2012002318A CL2012002318A CL2012002318A1 CL 2012002318 A1 CL2012002318 A1 CL 2012002318A1 CL 2012002318 A CL2012002318 A CL 2012002318A CL 2012002318 A CL2012002318 A CL 2012002318A CL 2012002318 A1 CL2012002318 A1 CL 2012002318A1
Authority
CL
Chile
Prior art keywords
mnk1
pharmaceutical composition
metabolic
neurodegenerative
hematopoietic
Prior art date
Application number
CL2012002318A
Other languages
English (en)
Inventor
Dieter Wiedenmayer
Joerg Kley
Lintz Thorsten Lehmann
Achim Sauer
Leo Thomas
Ian Linney
Matthias Austen
John Danilewicz
Martin Schneider
Kay Schreiter
Norbert Redemann
Phililip Black
Original Assignee
Boehringer Ingelheim Inernat Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43902874&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012002318(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Inernat Gmbh filed Critical Boehringer Ingelheim Inernat Gmbh
Publication of CL2012002318A1 publication Critical patent/CL2012002318A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos derivados de tienopirimidinas-heterocicloalquilo, inhibidores de Mnk1 o Mnk2; una sal de dicho compuesto; composición farmaceutica; y su uso para preparar un medicamento útil para la profilaxis o la terapia de enfermedades metabólicas, trastornos hematopoyéticos, enfermedades neurodegenerativas entre otras.
CL2012002318A 2010-02-26 2012-08-21 Compuestos derivados de tieno [2,3-d]pirimidina, inhibidores de quinasa mnk1 y mnk2; composición farmaceutica; que los comprende; y su uso en el tratamiento de enfermedades metabolicas, hematopoyeticas, neurodegenerativas, renales, inflamatorias y cancer. CL2012002318A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10154925 2010-02-26

Publications (1)

Publication Number Publication Date
CL2012002318A1 true CL2012002318A1 (es) 2012-11-23

Family

ID=43902874

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012002318A CL2012002318A1 (es) 2010-02-26 2012-08-21 Compuestos derivados de tieno [2,3-d]pirimidina, inhibidores de quinasa mnk1 y mnk2; composición farmaceutica; que los comprende; y su uso en el tratamiento de enfermedades metabolicas, hematopoyeticas, neurodegenerativas, renales, inflamatorias y cancer.

Country Status (16)

Country Link
US (1) US8648068B2 (es)
EP (1) EP2539346B1 (es)
JP (1) JP5639197B2 (es)
KR (1) KR20120130052A (es)
CN (1) CN102869669A (es)
AR (1) AR080327A1 (es)
AU (1) AU2011219761A1 (es)
BR (1) BR112012021264A2 (es)
CA (1) CA2791105A1 (es)
CL (1) CL2012002318A1 (es)
EA (1) EA201201193A1 (es)
MX (1) MX2012009409A (es)
PH (1) PH12012501691A1 (es)
TW (1) TW201141482A (es)
UY (1) UY33241A (es)
WO (1) WO2011104337A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5301986B2 (ja) * 2005-06-22 2013-09-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物用のチエノピリミジン類
EA200802118A1 (ru) * 2006-04-07 2009-04-28 Девелоджен Ациенгезельшафт Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях
EP1889847A1 (en) * 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
CA2735361A1 (en) 2008-08-26 2010-03-04 Boehringer Ingelheim International Gmbh Thienopyrimidines for pharmaceutical compositions
TW201141483A (en) * 2010-02-26 2011-12-01 Boehringer Ingelheim Int Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions
UY33241A (es) 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
EA201201191A1 (ru) 2010-02-26 2013-04-30 Бёрингер Ингельхайм Интернациональ Гмбх 4-[циклоалкилокси(гетеро)ариламино]тиено[2,3-d]пиримидины, обладающие ингибирующей активностью по отношению к mnkl/mnk2, предназначенные для фармацевтических композиций
NZ601847A (en) 2010-02-26 2014-03-28 Japan Tobacco Inc 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv integrase inhibitor
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
US10280168B2 (en) 2012-03-30 2019-05-07 Agency For Science, Technology And Research Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof
CN104507950B (zh) 2012-05-21 2017-03-22 拜耳医药股份有限公司 噻吩并嘧啶
CN104470931B (zh) 2012-05-21 2016-10-26 拜耳医药股份有限公司 取代的苯并噻吩并嘧啶
CA2880896C (en) 2012-06-26 2021-11-16 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
TW201412740A (zh) 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
JP2016506944A (ja) 2013-02-01 2016-03-07 バイエル・ファルマ・アクティエンゲゼルシャフト 置換ピラゾロピリミジニルアミノ−インダゾール
CN105189518A (zh) 2013-02-01 2015-12-23 拜耳制药股份公司 取代的噻吩并吡啶和其药物用途
US9675612B2 (en) 2013-03-06 2017-06-13 Bayer Pharma Aktiengesellschaft Substituted thiazolopyrimidines
US11491154B2 (en) 2013-04-08 2022-11-08 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
CN103356628B (zh) * 2013-08-02 2014-10-29 上海市第十人民医院 嗓唑并嘧啶类化合物在制药中的应用
CN103356625B (zh) * 2013-08-02 2014-10-29 上海市第十人民医院 嗓唑并嘧啶类在近平滑假丝酵母菌感染性疾病应用
CN103356627B (zh) * 2013-08-02 2014-10-29 上海市第十人民医院 一种药物在光滑假丝酵母菌感染性疾病应用
CN103356624B (zh) * 2013-08-02 2014-12-31 上海市第十人民医院 一种嘧啶类化合物在制备抗真菌药物中的应用
CN103417545B (zh) * 2013-08-02 2014-12-31 上海市第十人民医院 一种吡唑并嘧啶类化合物在制备抗烟曲霉菌感染性疾病药物中的应用
CN103356626B (zh) * 2013-08-02 2015-01-07 上海市第十人民医院 吡唑并嘧啶类化合物在制备抗红色毛癣菌感染疾病药物中的应用
US9512084B2 (en) * 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
CA2929742C (en) * 2013-12-04 2022-09-20 Evotec International Gmbh Sulfoximine substituted quinazolines for pharmaceutical compositions
WO2015091156A1 (en) * 2013-12-17 2015-06-25 Boehringer Ingelheim International Gmbh Sulfoximine substituted pyrrolotriazines for pharmaceutical compositions
ES2749186T3 (es) 2014-05-07 2020-03-19 Evotec Int Gmbh Quinazolinas sustituidas con sulfoximina para composiciones farmacéuticas
GB201520500D0 (en) * 2015-11-20 2016-01-06 Medical Res Council Technology Compounds
WO2017165908A1 (en) * 2016-03-31 2017-10-05 South Australian Health And Medical Research Institute Limited Method of inhibiting high fat diet-related conditions
WO2019023651A2 (en) * 2017-07-28 2019-01-31 Massachusetts Institute Of Technology MODULATORS OF THE SMALL MOLECULE ANDROGEN RECEPTOR
WO2025222091A1 (en) * 2024-04-19 2025-10-23 The Penn State Research Foundation Poly inflammatory kinase inhibitors and pharmaceutical compositions

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH408945A (de) 1956-02-10 1966-03-15 Ciba Geigy Verfahren zur Herstellung von heterocyclischen Verbindungen
DE3036390A1 (de) 1980-09-26 1982-05-13 Troponwerke GmbH & Co KG, 5000 Köln Neue pyrrolo-pyrimidine, verfahren zu ihrer herstellung und ihre verwendung bei der herstellung von biologischen wirkstoffen
DD248593A1 (de) 1985-01-11 1987-08-12 Univ Halle Wittenberg Verfahren zur herstellung von 4-basischsubstituierten thieno/2,3-d/pyrimidin-6-ylcarbonsaeureestern
DE4008726A1 (de) 1990-03-19 1991-09-26 Basf Ag Thieno(2,3-d)pyrimidinderivate
AU651337B2 (en) 1990-03-30 1994-07-21 Dowelanco Thienopyrimidine derivatives
TW444018B (en) 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
EP0682027B1 (de) 1994-05-03 1997-10-15 Novartis AG Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
EP0729758A3 (en) 1995-03-02 1997-10-29 Pfizer Pyrazolopyrimidines and pyrrolopyrimidines for the treatment of neuronal and other diseases
US6395733B1 (en) 1995-06-07 2002-05-28 Pfizer Inc Heterocyclic ring-fused pyrimidine derivatives
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
KR100446363B1 (ko) 1997-11-11 2004-09-01 화이자 프로덕츠 인코포레이티드 항암제로 유용한 티에노피리미딘 및 티에노피리딘 유도체
US20030162795A1 (en) 1998-10-22 2003-08-28 Pfizer Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
GB9906566D0 (en) 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
WO2000075145A1 (en) 1999-06-03 2000-12-14 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
US6643277B2 (en) 2000-06-29 2003-11-04 Harris Broadband Wireless Access, Inc. Frequency re-use for point to multipoint applications
JP2002020386A (ja) * 2000-07-07 2002-01-23 Ono Pharmaceut Co Ltd ピラゾロピリジン誘導体
CN101100472A (zh) 2001-04-30 2008-01-09 美国拜尔公司 4-氨基-5,6-取代的噻吩并[2,3-d]嘧啶化合物及其应用
SE0102147D0 (sv) 2001-06-18 2001-06-18 Pharmacia Ab New methods
US20050080026A1 (en) 2001-10-29 2005-04-14 Arnd Steuernagel Mnk kinase homologous proteins involved in the regulation of energy homeostasis and organelle metabolism
WO2004037159A2 (en) 2002-10-23 2004-05-06 Obetherapy Biotechnology Compounds, compositions and methods for modulating fat metabolism
US20050012622A1 (en) 2003-05-19 2005-01-20 Sutton William R. Monitoring and control of sleep cycles
CA2527496C (en) 2003-05-28 2012-08-14 Francesco Bondavalli 4-substituted derivatives of pyrazolo [3,4-d] pyrimidine and pyrrolo [2,3-d] pyrimidine and uses thereof
EA010297B1 (ru) 2003-06-20 2008-08-29 ЮСиБи ФАРМА С.А. Производные тиенопиридона как ингибиторы киназ
WO2005010008A1 (en) 2003-07-24 2005-02-03 Bayer Pharmaceuticals Corporation Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders
US7419978B2 (en) 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
DE10351436A1 (de) * 2003-11-04 2005-06-09 Merck Patent Gmbh Verwendung von Thienopyrimidinen
HRP20110035T1 (hr) 2004-01-05 2011-02-28 Merz Pharma Gmbh & Co. Kgaa Memantin za liječenje blage-do-umjerene alzheimer-ove bolesti
TW200538120A (en) 2004-02-20 2005-12-01 Kirin Brewery Compound having TGF-beta inhibitory activity and pharmaceutical composition containing same
EP1731523A4 (en) * 2004-04-01 2009-08-12 Takeda Pharmaceutical THIAZOLOPYRIMIDINDERIVAT
GB0412467D0 (en) 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
US7977345B2 (en) 2004-07-02 2011-07-12 Exelixis, Inc. c-MET modulators and method of use
EP1746099A1 (en) 2004-12-23 2007-01-24 DeveloGen Aktiengesellschaft Mnk1 or Mnk2 inhibitors
WO2006094791A1 (en) 2005-03-08 2006-09-14 Develogen Aktiengesellschaft Crystallographic structure of mnk-1 and mnk-2 proteins
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
BRPI0610322B8 (pt) 2005-05-20 2021-05-25 Methylgene Inc inibidores de sinalização de receptor de vegf e de receptor de hgf e composição farmacêutica
JP5301986B2 (ja) * 2005-06-22 2013-09-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物用のチエノピリミジン類
WO2007056214A2 (en) 2005-11-02 2007-05-18 Cytovia, Inc N-alkyl-n-aryl-thienopyrimidin-r-amines and uses thereof
WO2007056215A2 (en) 2005-11-02 2007-05-18 Cytovia, Inc. N-aryl-thienopyrimidin-4-amines and the use thereof
WO2007059905A2 (en) 2005-11-25 2007-05-31 Develogen Aktiengesellschaft Thienopyrimidines treating inflammatory diseases
WO2007081517A2 (en) 2005-12-21 2007-07-19 Abbott Laboratories Anti-viral compounds
US20080108611A1 (en) * 2006-01-19 2008-05-08 Battista Kathleen A Substituted thienopyrimidine kinase inhibitors
EA200802118A1 (ru) * 2006-04-07 2009-04-28 Девелоджен Ациенгезельшафт Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях
JP2009541268A (ja) 2006-06-22 2009-11-26 ビオヴィトルム・アクチボラゲット（プブリクト） Ｍｎｋキナーゼ阻害剤としてのピリジンおよびピラジン誘導体
EP1889847A1 (en) 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
CA2706203A1 (en) 2007-11-22 2009-05-28 Boehringer Ingelheim International Gmbh Use of mnk inhibitors for the treatment of alzheimer's disease
EP3150593B8 (en) * 2007-11-28 2019-08-21 Dana Farber Cancer Institute, Inc. Small molecule myristate inhibitors of bcr-abl and methods of use
US8112092B2 (en) 2008-01-25 2012-02-07 Sharp Kabushiki Kaisha Mobile station apparatus, program for controlling thereof and data transmitting method
US20100015708A1 (en) 2008-06-18 2010-01-21 Mdrna, Inc. Ribonucleic acids with non-standard bases and uses thereof
CA2735361A1 (en) 2008-08-26 2010-03-04 Boehringer Ingelheim International Gmbh Thienopyrimidines for pharmaceutical compositions
WO2011104338A1 (en) 2010-02-26 2011-09-01 Boehringer Ingelheim International Gmbh Halogen or cyano substituted thieno [2,3-d]pyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions
UY33241A (es) 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
EA201201191A1 (ru) 2010-02-26 2013-04-30 Бёрингер Ингельхайм Интернациональ Гмбх 4-[циклоалкилокси(гетеро)ариламино]тиено[2,3-d]пиримидины, обладающие ингибирующей активностью по отношению к mnkl/mnk2, предназначенные для фармацевтических композиций
TW201141483A (en) * 2010-02-26 2011-12-01 Boehringer Ingelheim Int Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions
ES2583015T3 (es) 2011-09-07 2016-09-16 Nordex Energy Gmbh Procedimiento para la fabricación de un componente de pala de rotor de instalación de energía eólica con un larguero principal prefabricado

Also Published As

Publication number Publication date
AU2011219761A1 (en) 2012-08-16
EA201201193A1 (ru) 2013-04-30
CN102869669A (zh) 2013-01-09
AR080327A1 (es) 2012-03-28
CA2791105A1 (en) 2011-09-01
US20110212102A1 (en) 2011-09-01
EP2539346B1 (en) 2014-04-16
KR20120130052A (ko) 2012-11-28
UY33241A (es) 2011-09-30
EP2539346A1 (en) 2013-01-02
BR112012021264A2 (pt) 2016-05-17
US8648068B2 (en) 2014-02-11
JP5639197B2 (ja) 2014-12-10
TW201141482A (en) 2011-12-01
WO2011104337A1 (en) 2011-09-01
PH12012501691A1 (en) 2012-11-05
MX2012009409A (es) 2012-09-07
JP2013520472A (ja) 2013-06-06

Similar Documents

Publication Publication Date Title
CL2012002318A1 (es) Compuestos derivados de tieno [2,3-d]pirimidina, inhibidores de quinasa mnk1 y mnk2; composición farmaceutica; que los comprende; y su uso en el tratamiento de enfermedades metabolicas, hematopoyeticas, neurodegenerativas, renales, inflamatorias y cancer.
CL2011000409A1 (es) Compuestos derivados de tieno[2,3-d]pirimidina; inhibidores de quinasa mnk1 y mnk2; composicion farmaceutica que los comprende y uso en el tratamiento de enfermedades metabolicas, hematopoyeticos, neurodegenerativas, renales, inflamatorias y cancer.
CL2012002319A1 (es) Compuestos derivados de amino-tienopirimidinas que contienen un grupo alquilo sustituido, inhibidores de mnk| o mnk2; composición farmacéutica; y su uso para la profilaxis o la terapia de enfermedades metabólicas, trastornos hematopoyéticos, enfermedades neurodegenerativas, cáncer, entre otras.
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
CL2014001158A1 (es) Compuestos derivados de piperazina alquilados; composicion farmaceutica que los comprende; proceso para preparar la composicion farmaceutica; kit y uso en el tratamiento de trastornos inmunes, cancer, enfermedades cardiovasculares, inflamacion, entre otros.
UY35590A (es) Nuevos compuestos para el tratamiento del cáncer
CL2016001537A1 (es) Inhibidores de syk
CL2012002317A1 (es) Compuestos derivados de tienopirimidinas, inhibitores de quinasas mnk1/mnk2; composicion farmaceutica; y su uso para elt ratamiento o profilaxis de enfermedades metabolicas, tales como diabetes, daño renal, cancer, enfermedades inflamatorias, entre otras.
CU20150163A7 (es) DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET
MX2016004360A (es) Inhibidores de kras g12c.
UY33921A (es) Oxazinopteridinas y oxazinoptiridinonas n-sustituidas
CL2014001103A1 (es) Compuestos derivados de heteroaril piridona y aza-piridona sustituidas, inhibidores de btk quinasa; composicion farmaceutica que los comprende; proceso de preparacion de la composicion farmaceutica; kit farmaceutico; y uso para el tratamiento de trastornos inmunes, cancer, inflamacion, trastornos neurologicos, entre otros.
CL2014002412A1 (es) Compuestos derivados de pirido[4,3-d]pirimidina, como inhibidores de mek; composicion farmaceutica que los comprende; y su uso para el tratamiento de enfermedades inflamatorias, infecciones, trastornos autoinmunes, enfermedades metabolicas y enfermedades malignas, entre otras.
CU20170172A7 (es) 4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos
CL2016001604A1 (es) “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
BR112012023660B8 (pt) usos de uma quantidade terapeuticamente eficaz de um composto, ou de um sal, solvato, hidrato ou pró-fármaco farmaceuticamente aceitável do mesmo para o tratamento de câncer
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
MX2019003605A (es) Formas solidas de un inhibidor de cdk4/6 selectivo.
HK1198475A1 (en) Heterocyclic compounds and uses thereof
CL2016000241A1 (es) Formulación de inhibidores de la syk.
NI201500059A (es) Inhibidores de la tirosina-quinasa de bruton
BR112014009031A2 (pt) formulações de etanercept estabilizadas com íons de metais
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
DOP2014000255A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
PE20150637A1 (es) Derivados de pirrolotriazinona como inhibidores de pi3k